Drug Type Peptide drug conjugates |
Synonyms BGC-0228, BGC0228 |
Target |
Action inhibitors |
Mechanism CD44 inhibitors(CD44 antigen inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | China | 15 Apr 2022 | |
| Breast Cancer | Phase 1 | China | 15 Apr 2022 | |
| Colorectal Cancer | Phase 1 | China | 15 Apr 2022 | |
| Metastatic Esophageal Carcinoma | Phase 1 | China | 15 Apr 2022 | |
| Ovarian Epithelial Carcinoma | Phase 1 | China | 15 Apr 2022 | |
| Pancreatic Cancer | Phase 1 | China | 15 Apr 2022 | |
| Stomach Cancer | Phase 1 | China | 15 Apr 2022 |





